Puche-Sanz I, Triviño-Ibáñez E, Vázquez-Alonso F, Llamas-Elvira J M, Cózar-Olmo J M, Rodríguez-Fernández A
UGC Urología, Complejo Hospitalario Universitario de Granada, Instituto de Investigación Biosanitaria IBS Granada (IBS Granada Bio-Health Research Institute), Granada, España.
UGC Medicina Nuclear, Complejo Hospitalario Universitario de Granada, Granada, Spain.
Actas Urol Esp. 2017 Sep;41(7):437-444. doi: 10.1016/j.acuro.2017.02.002. Epub 2017 Apr 25.
To analyse the ability of the PET-CT with F-fluorocholine (F-FCH) to detect disease on biochemical recurrence after treatment with curative intent. To determine the clinical variables that would be able to optimise the test's diagnostic yield.
A retrospective study of PET-CTs with F-fluorocholine performed on 61 patients with prostate cancer who had undergone treatment with curative intent and met the criteria for biochemical recurrence. The results of the PET-CT were categorised into positive or negative and were validated using pre-established criteria. The relationship between the result of the PET-CT and the initial PSA nadir, PSA trigger, rising PSA velocity (PSAva) and PSA doubling time (PSAdt). The relationship between the metastatic sites on the PET-CT and the remaining variables was analysed.
There was a 34.4% detection rate of the disease. The initial PSA, PSA nadir, PSA trigger and PSAva showed statistically significant differences according to the result of the PET-CT. The best discriminatory cut-off point between a positive or negative PET-CT for PSA trigger and PSAva was 3.5ng/ml and 0.25ng/ml/month respectively. The PSAdt was significantly lower in patients with remote disease compared to patients with localised disease (5.1 vs 16.8 months, P=.01). The probability that the PET-CT would detect remote disease vs localised disease was 3.2 times higher if the PSAdt was under 6 months (80% vs 20%, OR: 3.2, P=.02). In the multivariate analysis, only the initial PSA and not having undergone radical prostatectomy were demonstrated as independent predictive factors of a positive PET-CT result.
The PET-CT with F-FCH can detect disease in a high percentage of patients with biochemical recurrence and provides information on its anatomical location. PSA kinetics and the patient's previous treatment are key variables in increasing the test's diagnostic.
分析采用F-氟胆碱(F-FCH)的PET-CT在根治性治疗后生化复发时检测疾病的能力。确定能够优化该检查诊断率的临床变量。
对61例接受过根治性治疗且符合生化复发标准的前列腺癌患者进行的F-氟胆碱PET-CT回顾性研究。将PET-CT结果分为阳性或阴性,并根据既定标准进行验证。分析PET-CT结果与初始PSA最低点、PSA触发值、PSA上升速度(PSAva)和PSA倍增时间(PSAdt)之间的关系。分析PET-CT上的转移部位与其他变量之间的关系。
疾病检测率为34.4%。根据PET-CT结果,初始PSA、PSA最低点、PSA触发值和PSAva显示出统计学上的显著差异。PET-CT阳性或阴性的PSA触发值和PSAva的最佳鉴别临界点分别为3.5ng/ml和0.25ng/ml/月。与局限性疾病患者相比,远处疾病患者的PSAdt显著更低(5.1对16.8个月,P = 0.01)。如果PSAdt低于6个月,PET-CT检测远处疾病与局限性疾病的概率高3.2倍(80%对20%,OR:3.2,P = 0.02)。在多变量分析中,仅初始PSA和未接受根治性前列腺切除术被证明是PET-CT阳性结果的独立预测因素。
采用F-FCH的PET-CT能在高比例的生化复发患者中检测到疾病,并提供其解剖位置信息。PSA动力学和患者既往治疗是提高该检查诊断率的关键变量。